STX 1150
Alternative Names: STX-1150Latest Information Update: 08 Jan 2025
Price :
$50 *
At a glance
- Originator Scribe Therapeutics
- Class Antihyperlipidaemics; Gene therapies
- Mechanism of Action Gene silencing; PCSK9 protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hypercholesterolaemia
Most Recent Events
- 25 Nov 2024 Preclinical trials in Hypercholesteraolemia in USA (Parenteral) (Scribe Therapeutics Pipeline, December 2024)
- 25 Nov 2024 Pharmacodynamics and adverse events data from a preclinical study in Hypercholesteraolemia released by Scribe Therapeutics
- 16 Nov 2024 Pharmacodynamics data from a preclinical study in Hypercholesteraolemiapresented at the American Heart Association Scientific Sessions 2024 (AHA-2024)